| 1 | Abatacept | Abatacept [36] Abatacept; Abatacept (aba); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (ctla4-ig); Abatacept (iv); Abatacept (sc); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept active treatment; Abatacept delayed-onset treatment; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept sc; Abatacept subcutaneous; Abatacept, rituximab or tocilizumab; Adalimuab, etanercept, tocilizumab, or abatacept; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Bms 188667 (abatacept); Decrease tocilizumab, abatacept; Device: abatacept combination product (acp); Double-blind abatacept; Drug: abatacept; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Orencia® (abatacept); Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; | [1] D03203 D03203 💬 |
[2] CD80, CD86 💬 |
Allograft rejection [12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
011 [26] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬 |
| 2 | Activated charcoal | - | [1] D03251 D03251 💬 |
- |
- |
006 [9] 6 , 46, 50, 51, 85, 86, 96, 97, 298 💬 |
| 3 | Ajulemic acid | Ajulemic acid [2] Ajulemic acid; Resunab, ajulemic acid, anabasum; | [1] D11312 D11312 💬 |
[1] CNR2 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
050 [3] 50, 51, 299 💬 |
| 4 | Alendronic acid | Alendronic acid [1] Alendronic acid; | [2] D00939 D00939
D07119 D07119 💬 |
[1] FDPS 💬 |
Human T-cell leukemia virus 1 infection [4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
019 [7] 19, 41, 46, 50, 271, 274, 299 💬 |
| 5 | Alfacalcidol | Alendronate versus alfacalcidol (1-alpha oh vitamin d) [4] Alendronate versus alfacalcidol (1-alpha oh vitamin d); Alfacalcidol; Alfacalcidol 2 micrograms/ml; Ibandronate+alfacalcidol+calcium; | [1] D01518 D01518 💬 |
[1] VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption [4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
041 [6] 41, 46, 49, 50, 96, 235 💬 |
| 6 | Anakinra | Anakinra [8] Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra / kineret; Anakinra and peg stnf-r1; Kineret® (anakinra); Kineret® or anakinra; Response to anakinra associated with methotrexate; | [1] D02934 D02934 💬 |
[2] IL1R1, IL1R2 💬 |
Amoebiasis [15] Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
002 [19] 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬 |
| 7 | Apremilast | Apremilast [7] Apremilast; Apremilast (cc-10004); Apremilast 20 mg; Apremilast 30 mg; Apremilast 30mg; Apremilast tablet 20 mg; Apremilast tablet 30 mg bid; | [1] D08860 D08860 💬 |
[4] PDE4A, PDE4B, PDE4C, PDE4D 💬 |
Metabolic pathways [5] Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
046 [6] 46, 50, 56, 97, 162, 271 💬 |
| 8 | Baricitinib | Baricitinib [4] Baricitinib; Baricitinib, olumiant®; Tofacitinib or baricitinib; Tofacitinib/baricitinib; | [1] D10308 D10308 💬 |
[2] JAK1, JAK2 💬 |
AGE-RAGE signaling pathway in diabetic complications [33] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
041 [9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬 |
| 9 | Basiliximab | Basiliximab [1] Basiliximab; | [1] D03058 D03058 💬 |
[1] IL2RA 💬 |
Cytokine-cytokine receptor interaction [11] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
002 [7] 2 , 50, 65, 66, 97, 222, 228 💬 |
| 10 | Carbon dioxide | Carbon dioxide [3] Carbon dioxide; Device: fractional carbon dioxide laser; Device: fractionated carbon dioxide (fco2) laser; | [1] D00004 D00004 💬 |
- |
- |
050 [3] 50, 51, 97 💬 |
| 11 | Chloride ion | - | - |
- |
- |
006 [25] 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 97, 127, 168, 171, 193, 227, 228, 271, 288, 296, 297, 299 💬 |
| 12 | Corticotropin | Adrenocorticotropin hormone [8] Adrenocorticotropin hormone; Corticotropin; Corticotropin-releasing hormone; H.p. acthar gel (repository corticotropin injection); Other: corticotropin releasing hormone (crh); Ovine corticotropin-releasing hormone (ocrh); Repository corticotropin injection; Repository corticotropin injection -treatment extension; | [1] D00146 D00146 💬 |
[1] MC2R 💬 |
Aldosterone synthesis and secretion [5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
002 [13] 2 , 13, 14, 46, 49, 50, 66, 75, 78, 84, 145, 193, 222 💬 |
| 13 | Creatine | Creatine [4] Creatine; Creatine monohydrate; Creatine-13c; Pyruvate, creatine, niacinamide; | - |
- |
- |
001 [12] 1 , 2 , 5 , 6 , 8 , 13, 46, 49, 50, 113, 156, 201 💬 |
| 14 | Cyclophosphamide | Busulfan, cyclophosphamide, antithymocyte globulin [55] Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Busulfan, cyclophosphamide, atg, gcsf; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Campath, fludarabine, cyclophosphamide; Cyclophosphamide; Cyclophosphamide (cy); Cyclophosphamide (cy) (plan 1); Cyclophosphamide (cy) (plan 2); Cyclophosphamide (cytoxan); Cyclophosphamide (drug); Cyclophosphamide + pred; Cyclophosphamide 100mg; Cyclophosphamide 150mg; Cyclophosphamide 30; Cyclophosphamide 40; Cyclophosphamide 50mg; Cyclophosphamide 50mg oral tablet; Cyclophosphamide and atg; Cyclophosphamide and fludarabine; Cyclophosphamide and steroids; Cyclophosphamide dose level 1; Cyclophosphamide dose level 2; Cyclophosphamide dose level 3; Cyclophosphamide dose level 4; Cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids; Cyclophosphamide injection 1g; Cyclophosphamide monohydrate; Cyclophosphamide post transplant; Cyclophosphamide(ctx); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide, bortezomib, and dexamethasone (cybord); Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Cyclophosphamide, fludarabine; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Cyclophosphamide,campath ih and tbi; Cyclophosphamide,cyclosporine a; Cyclophosphamide-prednisone-azathioprine; Cyclophosphamide/glatiramer acetate; Fludarabine, cyclophosphamide; Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide''; High-dose cyclophosphamide; Iv cyclophosphamide; Lenalidomide, dexamethasone and cyclophosphamide; Prednisone and cyclophosphamide; Prednisone plus cyclophosphamide; Prednisone, cyclophosphamide; Prednisone, methylprednisolone,cyclophosphamides; Procedure: cyclophosphamide; Rituximab and cyclophosphamide iv; Thalidomide, cyclophosphamide and prednisone; | [2] D00287 D00287
D07760 D07760 💬 |
- |
- |
011 [44] 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 💬 |
| 15 | Cyclosporine | Atg+cyclosporine [26] Atg+cyclosporine; Atg+rapamune+cyclosporine; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Cyclophosphamide,cyclosporine a; Cyclosporine; Cyclosporine (gengraf ); Cyclosporine (usan); Cyclosporine 5 mg/kg bid days 0-14; Cyclosporine a; Cyclosporine a (csa); Cyclosporine a dry powder inhalation (drug); Cyclosporine combine with mycophenolate mofetil; Cyclosporine inhalation solution; Cyclosporine inhalation solution (cis); Cyclosporine oral product; Cyclosporine pill; Cyclosporine vs infliximab; Cyclosporine-a; Device: cyclosporine a; Liposomal aerosol cyclosporine; Liposomal cyclosporine a; Liposomal cyclosporine a 10 mg; Liposomal cyclosporine a 5 mg; Oral cyclosporine; Rabbit atg, cyclosporine, levamisole; Twice-daily dosage with 0.5% cyclosporine-a eyedrops; | [1] D00184 D00184 💬 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
011 [43] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬 |
| 16 | Denosumab | Denosumab [5] Denosumab; Denosumab - - immunoglobulin g2 human monoclonal antibody to rank ligand; Denosumab - immunoglobulin g2 human monoclonal antibody to rank ligand; Pralia 60 mg subcutaneous injection syringe(denosumab); Pralia 60mg subcutaneous injection syringe(denosumab); | [1] D03684 D03684 💬 |
[1] TNFSF11 💬 |
Breast cancer [7] Breast cancer, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis |
046 [7] 46, 50, 93, 95, 96, 274, 299 💬 |
| 17 | Dextrose, unspecified form | - | - |
- |
- |
002 [18] 2 , 6 , 13, 49, 50, 56, 60, 65, 70, 75, 86, 88, 96, 160, 195, 254, 257, 299 💬 |
| 18 | Etanercept | 50 mg etanercept [49] 50 mg etanercept; Adalimuab, etanercept, tocilizumab, or abatacept; Adalimumab, etanercept, golimumab or infliximab; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Commercial formulation etanercept; Enbrel (etanercept); Etanercept; Etanercept (50mg per week); Etanercept (50mg per week, for 2 weeks); Etanercept (50mg per week, for 4 weeks); Etanercept (enbrel); Etanercept (enbreltm); Etanercept (etn); Etanercept (full-dose); Etanercept (half-dose); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept / autoinjector a; Etanercept 50 mg sc day 0 and day 3; Etanercept 50 mg/ml; Etanercept 50mg; Etanercept auto-injector; Etanercept biosimilar; Etanercept liquid; Etanercept optimal dosing; Etanercept or adalimumab; Etanercept pre-filled syringe; Etanercept pre-filled syringe sq injection; Etanercept treatment; Etanercept via autoinjector a; Etanercept via autoinjector b; Etanercept, methotrexate and depomedrone; Etanercept, methotrexate, prednisolone; Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Lyophilized etanercept powder(yisaipu); Methotrexate - etanercept - prednisolone arm; New formulation etanercept; Phase 1: etanercept; Prefilled liquid etanercept(yisaipu); Procedure: intra-articular injection of etanercept; Reumatocept (etanercept); Sb4 (etanercept biosimilar); Sb4 (proposed biosimilar to etanercept); Tapering or discontinuation of etanercept; Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); | [1] D00742 D00742 💬 |
[2] LTA, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
015 [15] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 228, 271, 285, 298 💬 |
| 19 | Gevokizumab | Gevokizumab [2] Gevokizumab; Gevokizumab open-label; | [1] D09911 D09911 💬 |
[1] IL1B 💬 |
AGE-RAGE signaling pathway in diabetic complications [42] AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection |
041 [4] 41, 50, 56, 269 💬 |
| 20 | Gold | Gold [7] Gold; Gold nanocrystals; Mtx goldshield tablets; Other: comparator: cpet cycle ergometer (gold standard); Procedure: quantiferon-tb gold assay; Procedure: repair of cdh w/sis gold; Sodium aurothiomalate (intramuscular gold); | - |
- |
- |
002 [38] 2 , 5 , 6 , 13, 17, 34, 46, 49, 50, 53, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 158, 162, 171, 218, 222, 224, 227, 230, 271, 291, 294, 296, 298, 299, 310, 318 💬 |
| 21 | Grapefruit | Grapefruit [2] Grapefruit; Grapefruit juice; | - |
- |
- |
006 [5] 6 , 46, 50, 83, 97 💬 |
| 22 | Haemagglutinin-strain B | - | - |
- |
- |
021 [4] 21, 46, 49, 50 💬 |
| 23 | Hepatitis B Vaccine (Recombinant) | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 24 | Human immunoglobulin G | Human immunoglobulin g [2] Human immunoglobulin g; Normal human immunoglobulin g; | - |
- |
- |
011 [11] 11, 13, 14, 17, 35, 43, 45, 50, 51, 63, 65 💬 |
| 25 | Human papillomavirus type 16 L1 capsid protein antigen | - | - |
- |
- |
049 [2] 49, 50 💬 |
| 26 | Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen | - | - |
- |
- |
049 [2] 49, 50 💬 |
| 27 | Human papillomavirus type 18 L1 capsid protein antigen | - | - |
- |
- |
049 [2] 49, 50 💬 |
| 28 | Human papillomavirus type 18 l1 capsid protein residues 2-472 antigen | - | - |
- |
- |
049 [2] 49, 50 💬 |
| 29 | Infliximab | 99m technetium infliximab [70] 99m technetium infliximab; 99mtc-infliximab; Abp 710 - biosimilar to infliximab; Adalimumab and infliximab; Adalimumab, etanercept, golimumab or infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Ct-p13 sc (infliximab); Cyclosporine vs infliximab; Inflectra (infliximab); Infliximab; Infliximab (bcd-055); Infliximab (ifx alone); Infliximab (ifx); Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 20 mg/kg; Infliximab 3 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab [infliximab biosimilar 3]; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab and mtx; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-biosimilar; Infliximab-eu; Infliximab-innovator; Infliximab-pfizer; Innovator infliximab; Intravitreal infliximab; Methotrexate + infliximab; Other: infliximab (ifx) infusion; Other: measurement of drug (adalimumab/infliximab); Procedure: measurement of serum infliximab and anti-infliximab antibodies; Procedure: treatment according to current standards without knowledge of serum infliximab and anti-infliximab ab status; Remicade (infliximab); Remicade® (infliximab); Remicaide (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Topical infliximab; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); | [1] D02598 D02598 💬 |
[1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
035 [25] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬 |
| 30 | KZR-616 | Kzr-616 [2] Kzr-616; Kzr-616 maleate; | - |
- |
- |
049 [3] 49, 50, 61 💬 |
| 31 | Methimazole | Methimazole [1] Methimazole; | [1] D00401 D00401 💬 |
[1] TPO 💬 |
Autoimmune thyroid disease [4] Autoimmune thyroid disease, Metabolic pathways, Thyroid hormone synthesis, Tyrosine metabolism |
050 [1] 50 💬 |
| 32 | Methotrexate | Abatacept (aba) + methotrexate (mtx), double-blind (db) [113] Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Azathioprine or methotrexate; Bms-582949 and methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Certolizumab pegol + methotrexate (mtx); Clobetasol propionate + methotrexate; Combination product: methotrexate; Cp-690,550 + methotrexate; Cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids; Cyclosporin, methotrexate (gvhd prophylaxis); Dmards (methotrexate; Early immunosuppressants (azathioprine, methotrexate); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept, methotrexate and depomedrone; Etanercept, methotrexate, prednisolone; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Intrathecal methotrexate; Methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate 'lederle' tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate (stable dose); Methotrexate (tapering dose); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 10 mg; Methotrexate 10 mg tablets; Methotrexate 2.5 mg; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 25 mg; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate ``lederle`` 2.5mg tablets; Methotrexate and folic acid; Methotrexate as methotrexate disodium; Methotrexate bellon; Methotrexate bellon 25mg/ml; Methotrexate capsules; Methotrexate disodium; Methotrexate ebewe; Methotrexate hospira 2,5 mg tablety; Methotrexate hospira 2.5 mg tablety; Methotrexate injection; Methotrexate lachema 5inj. sol; Methotrexate lederle 2.5 mg tablets; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate sodium tablets 2.5mg; Methotrexate tablets; Methotrexate tablets 2.5 mg; Methotrexate treatment; Methotrexate wyeth 2,5mg; Methotrexate wyeth 2,5mg tbl.; Methotrexate ® 2.5mg tablets; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol; Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate*10mg/1,33ml 4s; Methotrexate*15mg/2ml 4sir; Methotrexate*2,5mg 25cpr; Methotrexate*20mg/2,66ml 4s; Methotrexate*25cpr 2,5mg; Methotrexate*7,5mg/ml 4sir.; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Mycophenolate mofetil,methotrexate; Oral methotrexate; Other: methotrexate therapy; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tak-715 and methotrexate; Tak-783 and methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab plus methotrexate; Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Treatment with systemic therapy (methotrexate); Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; | [2] D00142 D00142
D02115 D02115 💬 |
[2] DHFR, DHFR2 💬 |
Antifolate resistance [5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
011 [35] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬 |
| 33 | Methylprednisolone | Administration of rituximab and methylprednisolone [35] Administration of rituximab and methylprednisolone; Corticosteroid treatment (methylprednisolone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Infliximab, methylprednisolone, methotrexate; Interferon-beta-1a (avonex) plus methylprednisolone; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone (solu-medrol); Methylprednisolone 1250 mg/24h x3 days; Methylprednisolone acetate; Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone po; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Oral methylprednisolone 625 mg/24h x3 days; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; | [6] D00407 D00407
D00751 D00751
D00979 D00979
D05000 D05000
D05001 D05001
D05002 D05002 💬 |
[1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [44] 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
| 34 | Methylprednisolone hemisuccinate | Methylprednisolone hemisuccinate [1] Methylprednisolone hemisuccinate; | [1] D05000 D05000 💬 |
[1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
013 [7] 13, 49, 50, 51, 53, 97, 211 💬 |
| 35 | Monomethyl fumarate | Monomethyl fumarate [2] Monomethyl fumarate; Monomethyl fumarate 190 mg; | [1] D11492 D11492 💬 |
- |
- |
013 [13] 13, 35, 40, 49, 50, 51, 60, 65, 66, 222, 224, 226, 299 💬 |
| 36 | Nifedipine | 10% nifedipine cream [2] 10% nifedipine cream; Nifedipine; | [1] D00437 D00437 💬 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes [36] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
050 [2] 50, 81 💬 |
| 37 | Nivolumab | Nivolumab [1] Nivolumab; | [1] D10316 D10316 💬 |
[1] PDCD1 💬 |
Cell adhesion molecules [3] Cell adhesion molecules, PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
013 [12] 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬 |
| 38 | Pirfenidone | Pirfenidone [7] Pirfenidone; Pirfenidone (pfd); Pirfenidone 267 mg [esbriet]; Pirfenidone and nintedanib; Pirfenidone or nintedanib; Pirfenidoneone; Sub-study: pirfenidone; | [1] D01583 D01583 💬 |
[6] CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [82] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
034 [10] 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬 |
| 39 | Prednisolone | Administration of rituximab and methylprednisolone [96] Administration of rituximab and methylprednisolone; Azd4017 and prednisolone; Combination therapy with vigabatrin and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroid (prednisolone); Corticosteroid treatment (methylprednisolone or prednisolone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Etanercept, methotrexate, prednisolone; Glucocorticoid (prednisone or prednisolone); Infliximab, methylprednisolone, methotrexate; Interferon-beta-1a (avonex) plus methylprednisolone; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methyl prednisolone; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Lodotra (delayed release prednisolone); Long-circulating liposomal prednisolone; Low dose prednisolone; Medium dose prednisolone; Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methotrexate - etanercept - prednisolone arm; Methyl prednisolone; Methyloprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone (solu-medrol); Methylprednisolone 1250 mg/24h x3 days; Methylprednisolone acetate; Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone po; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Metilprednisolone; Metilprednisolone sodio succinato; Méthylprednisolone; Méthylprednisolone mylan; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Oral methylprednisolone 625 mg/24h x3 days; Oral prednisolone; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Paroxetine hydrochloride tablets 10 & 20 mg and prednisolone 1 mg bp; Peg-liposomal prednisolone sodium phosphate; Prednisolone; Prednisolone & dipyridamole; Prednisolone + mabthera; Prednisolone 1mg tablets; Prednisolone 2,5 mg tablets; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone 5 mg jenapharm; Prednisolone 5 mg tablets; Prednisolone 5mg gastro-resistant tablets; Prednisolone 5mg tablet; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisolone and taper; Prednisolone labesfal; Prednisolone sodium metasulphobenzoate; Prednisolone sodium phosphate; Prednisolone sodium succinate; Prednisolone tablets b.p. 5mg; Prednisolone tablets bp; Prednisolone tablets bp 1 mg; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednisolone/prednisone; Prednisone (and methylprednisolone); Prednisone or prednisolone; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; [metilprednisolone sodio succinato]; [metilprednisolone]; | [8] D00472 D00472
D00980 D00980
D00981 D00981
D00982 D00982
D01239 D01239
D01998 D01998
D02156 D02156
D03301 D03301 💬 |
[1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
011 [40] 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬 |
| 40 | Prednisone | 0 mg prednisone [73] 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; Adalimumab, plus prednisone; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Enalapril valsartan methylprednisone; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Ir prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Methylprednisone; Mr prednisone; Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Other: prednisone; Over encapsulated prednisone; Prednisolone/prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 1 mg; Prednisone 15 mg; Prednisone 2 mg; Prednisone 3 mg; Prednisone 4 mg; Prednisone 5 mg; Prednisone 5 mg tablets; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and belimumab; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, ciclosporin and mycophenolate mofetil; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, low dose rituximab; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Procedure: thymectomy plus prednisone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); Ursodeoxycholic acid+low dose glucocorticoid(prednisone); | [1] D00473 D00473 💬 |
[1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
002 [47] 2 , 6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬 |
| 41 | Risedronic acid | Risedronic acid [1] Risedronic acid; | [3] D00942 D00942
D03234 D03234
D08484 D08484 💬 |
[1] FDPS 💬 |
Human T-cell leukemia virus 1 infection [4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
046 [8] 46, 50, 66, 93, 95, 96, 113, 274 💬 |
| 42 | Rituximab | Abatacept, rituximab or tocilizumab [67] Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Abp 798 biosimilar to rituximab; Administration of rituximab and methylprednisolone; Alemtuzumab and rituximab; Alemtuzumab, rituximab; Bendamustine, rituximab; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Combined plasma exchange (pex), rituximab, and corticosteroids; Dexamethasone and rituximab; Double-blind rituximab; Dr. reddy’s rituximab (drl_ri) 100mg; Dr. reddy’s rituximab (drl_ri) 500mg; Eltrombopag combining rituximab; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Immunosuppressive treatment (eg, rituximab); Individualized dose of rituximab; Intravenous rituximab; Mabthera (rituximab); Mabthera or biosimilar rituximab product; Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Prednisone, low dose rituximab; Rhtpo in combination with rituximab; Rituxan (inn: rituximab), brand name in the united states; Rituxan (inn: rituximab), brand name in the us; Rituxan (rituximab); Rituxan® (rituximab); Rituximab; Rituximab (anti-cd20); Rituximab (arm a); Rituximab (arm b); Rituximab (eu); Rituximab (genetical recombination); Rituximab (mabthera® or rituxan®).; Rituximab (mabthera®); Rituximab (rituxan); Rituximab (rtx) and azathioprine (aza); Rituximab (us); Rituximab - mabthera; Rituximab 1g iv; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab and cyclophosphamide iv; Rituximab combined with omalizumab; Rituximab infusion; Rituximab it; Rituximab iv; Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml; Rituximab mabthera; Rituximab or rituximab hyaluronidase human; Rituximab, mabthera; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Rituximab/ mabthera; Sait101 (proposed rituximab biosimilar); Sait101 (rituximab biosimilar); Standard dose of rituximab; The standard steroid treatment, plasma exchange and rituximab; [rituximab]; | [1] D02994 D02994 💬 |
[1] MS4A1 💬 |
Hematopoietic cell lineage [1] Hematopoietic cell lineage |
011 [47] 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬 |
| 43 | Sildenafil | 20 mg sildenafil citrate by mouth [32] 20 mg sildenafil citrate by mouth; 5% sildenafil cream; Access program - sildenafil citrate, viagra, revatio; Bosentan and sildenafil; Duo-therapy with sildenafil + bosentan; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); G04be03- sildenafil - sildenafil (citrato); Mono-therapy with sildenafil; Oral sildenafil; Other: standard of care sildenafil; Sildenafil; Sildenafil (50 mg); Sildenafil (acute-1 hour); Sildenafil (as citrate); Sildenafil (revatio); Sildenafil (revatio) 20 mg tid; Sildenafil (subchronic-4 weeks); Sildenafil 20 mg tablets; Sildenafil 20mg; Sildenafil 20mg and bosentan 62.5mg; Sildenafil 40mg oral capsule; Sildenafil and losartan; Sildenafil by injection; Sildenafil citrate; Sildenafil citrate (uk-92,480); Sildenafil filmtabletten; Sildenafil singly or in association with bosentan; Sildenafil therapy; Sildenafilo; Sitaxsentan and sildenafil; Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth; Tadalafil and sildenafil; | [2] D02229 D02229
D08514 D08514 💬 |
[1] PDE5A 💬 |
Metabolic pathways [3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
006 [17] 6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬 |
| 44 | Siponimod | Siponimod [5] Siponimod; Siponimod 0.25 mg tablet; Siponimod 0.5 mg tablet; Siponimod 1 mg tablet; Siponimod 2 mg tablet; | [1] D11460 D11460 💬 |
[2] S1PR1, S1PR5 💬 |
FoxO signaling pathway [3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
013 [2] 13, 50 💬 |
| 45 | Sodium chloride | 0.9% sodium chloride [24] 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v isotonic sodium chloride solution; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Other: 0.9% sodium chloride; Other: 0.9ml sodium chloride; Other: sodium chloride; Physiological serum (sodium chloride); Procedure: 9% sodium chloride (nacl) iv; Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 0.9%; Sodium chloride 6%; Sodium chloride 7%; Sodium chloride ph. eur.; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution; Solucion de cloruro de sodio sodium chloride solution; Solvente cloruro de sodio sodium chloride solvent; | [1] D02056 D02056 💬 |
- |
- |
006 [20] 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 168, 193, 227, 228, 271, 288, 299 💬 |
| 46 | Sodium tetradecyl sulfate | - | [1] D06882 D06882 💬 |
- |
- |
050 [2] 50, 51 💬 |
| 47 | Streptococcus pneumoniae type 1 capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 48 | Streptococcus pneumoniae type 10a capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 49 | Streptococcus pneumoniae type 11a capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 50 | Streptococcus pneumoniae type 12f capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 51 | Streptococcus pneumoniae type 14 capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 52 | Streptococcus pneumoniae type 15b capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 53 | Streptococcus pneumoniae type 17f capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 54 | Streptococcus pneumoniae type 18c capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 55 | Streptococcus pneumoniae type 19a capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 56 | Streptococcus pneumoniae type 19f capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 57 | Streptococcus pneumoniae type 2 capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 58 | Streptococcus pneumoniae type 20 capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 59 | Streptococcus pneumoniae type 22f capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 60 | Streptococcus pneumoniae type 23f capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 61 | Streptococcus pneumoniae type 3 capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 62 | Streptococcus pneumoniae type 33f capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 63 | Streptococcus pneumoniae type 4 capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 64 | Streptococcus pneumoniae type 5 capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 65 | Streptococcus pneumoniae type 6b capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 66 | Streptococcus pneumoniae type 7f capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 67 | Streptococcus pneumoniae type 8 capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 68 | Streptococcus pneumoniae type 9n capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 69 | Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - |
- |
- |
046 [2] 46, 50 💬 |
| 70 | Tacrolimus | Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf [17] Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Rectal tacrolimus; Symptomatic treatment, steroids, immunosuppressive agents( azathioprine, tacrolimus, mycophenolate mofetil); Tacrolimus; Tacrolimus (advagraf); Tacrolimus (prograf®); Tacrolimus (tacro); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsule (low-dose); Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus tablets; Tacrolimus with methotrexate; | [2] D00107 D00107
D08556 D08556 💬 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
002 [32] 2 , 6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬 |
| 71 | Tocilizumab | Abatacept, rituximab or tocilizumab [39] Abatacept, rituximab or tocilizumab; Adalimuab, etanercept, tocilizumab, or abatacept; Corticoids+ tocilizumab 8mg/kg/4 weeks; Decrease tocilizumab, abatacept; Etanercepet, rituximab, abatacept, tocilizumab, sarilumab; Inn-tocilizumab; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab; Tocilizumab (actemra or roactemra); Tocilizumab (actemra); Tocilizumab (actemra®); Tocilizumab (mra-sc); Tocilizumab (tcz); Tocilizumab + glucocorticoids (gcs); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab 162mg/0.9ml sc pfs sc; Tocilizumab 162mg/0.9ml syringe sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab and iv steroids combination; Tocilizumab infusion roacemtra (eu); Tocilizumab injection; Tocilizumab iv; Tocilizumab plus methotrexate; Tocilizumab prefilled syringe; Tocilizumab roche; Tocilizumab sc; Tocilizumab sc 162 mg/0.9 ml disposable auto-injector (ai); Tocilizumab sc 162 mg/0.9 ml pre-filled syringe with safety device (pfs); Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Tocilizumab treatment; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; Tocilizumabum; | [1] D02596 D02596 💬 |
[1] IL6R 💬 |
Coronavirus disease - COVID-19 [12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
002 [18] 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬 |
| 72 | Tofacitinib | 15n2-tofacitinib [36] 15n2-tofacitinib; Chong kun dang tofacitinib tablet; Cp-690,550 (tofacitinib); In double-blind phase: treatment with tofacitinib; In open-label phase: treatment with tofacitinib; Tofacitinib; Tofacitinib (cp-690,550); Tofacitinib (xeljanz); Tofacitinib (xeljanz®); Tofacitinib (xeljanz®) 11mg prolonged release tablet; Tofacitinib 10 mg; Tofacitinib 2 mg; Tofacitinib 5 mg; Tofacitinib 5 mg [xeljanz]; Tofacitinib 5 mg twice daily; Tofacitinib 5mg [xeljanz] 1 year open-label extension; Tofacitinib 5mg oral tablet [xeljanz] 16 week trial; Tofacitinib 5mg po bid; Tofacitinib citate (phase iii formulation); Tofacitinib citrate; Tofacitinib citrate (clinical trial image); Tofacitinib citrate (commercial image); Tofacitinib citrate (phase iii formulation); Tofacitinib citrate (proposed commercial formulation - debossed); Tofacitinib citrate (proposed commercial formulation debossed); Tofacitinib citrate (proposed commercial formulation – debossed); Tofacitinib citrate (proposed commercial formulation- debossed); Tofacitinib citrate (proposed commercialformulation - debossed); Tofacitinib citrate cp-690550; Tofacitinib citrate( phase iii formulation); Tofacitinib or baricitinib; Tofacitinib tablet; Tofacitinib with methotrexate; Tofacitinib without methotrexate; Tofacitinib/baricitinib; Tofacitinibe citrate; | [1] D09970 D09970 💬 |
[4] JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications [35] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
011 [12] 11, 40, 46, 49, 50, 51, 53, 84, 96, 97, 107, 271 💬 |
| 73 | Topramezone | - | - |
- |
- |
006 [8] 6 , 13, 46, 50, 53, 96, 97, 299 💬 |
| 74 | Ustekinumab | Evaluation of biological predictive factors of clinical response to ustekinumab [36] Evaluation of biological predictive factors of clinical response to ustekinumab; Group 2 ustekinumab 130 mg; Group 3: ustekinumab approximately 6 mg/kg; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Prednisone and ustekinumab treatment; Stelara (ustekinumab); Subcutaneous ustekinumab; Ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab (approximately 6 mg/kg); Ustekinumab + mtx (group 2); Ustekinumab + mtx (group 3); Ustekinumab 130 mg iv; Ustekinumab 180 mg; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 45 mg; Ustekinumab 6 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg; Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab 90 milligram (mg); Ustekinumab approximately 6 mg/kg (iv); Ustekinumab dose based on bsa and body weight; Ustekinumab iv; Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab liquid in prefilled syringe; Ustekinumab sc; Ustekinumab sc injection; | [1] D09214 D09214 💬 |
[3] IL12A, IL12B, IL23A 💬 |
African trypanosomiasis [26] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
037 [15] 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬 |
| 75 | Vitamin D | 10000iu vitamin d [36] 10000iu vitamin d; 19 nor vitamin d; 25-hydroxyvitamin d3; 25oh-vitamin d; 5000iu vitamin d; Alendronate versus alfacalcidol (1-alpha oh vitamin d); Calcium and vitamin d combination; Cholecalciferol (vitamin d3); Cholecalciferol, vitamin d3; D6-25-hydroxyvitamin d3; Diagnostic test: vitamin d measurement; Ergocalciferol (vitamin d2); High-dose vitamin d (2000 iu per day); High-dose vitamin d3; Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Other: baseline serum vitamin d level at or above 50 nmol/l; Other: baseline serum vitamin d level below 50 nmol/l; Standard-dose vitamin d (400iu per day); Supplementation with vitamin d2/d3; Verum arm receiving vitamin d oil; Vitamin d; Vitamin d 100ug; Vitamin d 10ug; Vitamin d 25(oh)d; Vitamin d drops; Vitamin d in arm b; Vitamin d oil; Vitamin d powder; Vitamin d2; Vitamin d3; Vitamin d3 3000 ui daily; Vitamin d3 400 iu; Vitamin d3 4000 ui daily; Vitamin d3 6000 iu; Vitamin d3 800 ui/day then 800 ui/day; Vitamin d3: 3000 or 4000 ui/day then 2,000 ui/day; | - |
- |
- |
013 [21] 13, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 274, 298, 299 💬 |
| 76 | Yellow Fever Vaccine | Yellow fever vaccine [2] Yellow fever vaccine; Yellow fever vaccine (17d); | [1] D06347 D06347 💬 |
- |
- |
040 [7] 40, 44, 46, 50, 51, 52, 53 💬 |